COMMUNIQUÉS West-GlobeNewswire

Press release: Sequana Medical to Attend the “VFB Happening 2025” in Ghent, Belgium on Saturday, 29 March 2025
27/03/2025
Sequana Medical to Attend the “VFB Happening 2025” in Ghent, Belgium on Saturday, 29 March 2025 Ghent, Belgium – 27 March 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical") , a [...]
Santhera proposes Dr. Melanie Rolli as new member of Board of Directors
27/03/2025
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 27, 2025 – Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Melanie Rolli as an Independent Director at the upcoming Annual General [...]
Idorsia publishes its Annual Report 2024
27/03/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 27, 2025 Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 – consisting of the Business Report, Governance Report [...]
Amaran Biotech Wins "Best CDMO in Automated Aseptic Filling"
27/03/2025
Honored at Taiwan Biopharma Excellence Awards 2025 TAIPEI, Taiwan, March 27, 2025 (GLOBE NEWSWIRE) -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), was honored with the " [...]
Junshi Biosciences Announces Toripalimab’s Approval in Singapore
27/03/2025
SHANGHAI, March 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva
27/03/2025
PALO ALTO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
Ryoncil® is Now Available for Purchase in the United States
27/03/2025
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil ® (remestemcel-L) the first [...]
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
26/03/2025
Receives Court Approval for First Day Motions to Support Ongoing Business Operations SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME), a leading human [...]
Alvotech Reports Record Results for 2024 and Provides Business Update
26/03/2025
Total Revenues in 2024 reached $492 million, representing a 427% increase over prior year Product Revenues in 2024 reached $273 million, representing a 462% increase over prior year Adjusted EBITDA in 2024 was $108.3 [...]
Alvotech Reports Record Results for 2024 and Provides Business Update
26/03/2025
Total Revenues in 2024 reached $492 million, representing a 427% increase over prior year Product Revenues in 2024 reached $273 million, representing a 462% increase over prior year Adjusted EBITDA in 2024 was $108.3 [...]
Soleno Therapeutics Announces U.S. FDA Approval of VYKAT(TM) XR to Treat Hyperphagia in Prader-Willi Syndrome
26/03/2025
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26 th , at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE [...]
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
26/03/2025
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a [...]
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
26/03/2025
In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission [...]
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025
26/03/2025
Monrovia, CA , March 26, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels [...]
Tilray Successfully Prevails with Dismissal of HEXO Shareholder Lawsuit
26/03/2025
NEW YORK and LEAMINGTON, Ontario, March 26, 2025 (GLOBE NEWSWIRE) -- Tilray Brands Inc. (“ Tilray ”) (Nasdaq: TLRY; TSX: TLRY), and its subsidiary HEXO Corporation (“ HEXO ”), announced the successful dismissal of the [...]
BioCardia Reports 2024 Business Highlights and Financial Results
26/03/2025
SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
Solésence Reports Record Fourth Quarter and Full-Year 2024 Financial Results
26/03/2025
Fourth quarter revenue increased 58% to a record $12.6 million Full Year 2024 revenue increased 40% to a record $52.3 million ROMEOVILLE, Ill., March 26, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader [...]
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors
26/03/2025
WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on [...]
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
26/03/2025
Experimental treatment with CAN-2409 was associated with a median overall survival (mOS) of 24.5 months in patients with advanced NSCLC who had an inadequate response to ICI treatment, failed several chemotherapy [...]

Pages